

Antibiotic Resistance Profiles of Bacteria Isolated from Patients Hospitalized at the Sylvanus Olympio University Teaching Hospital in Lomé, Togo

Abstract

Aims: Bacteria isolated from hospitalized patients are often responsible for healthcare-associated infections (HAI), particularly in developing countries. Thus, this study aimed to determine the antibiotic resistance profiles of bacteria isolated from patients hospitalized at the Sylvanus Olympio University Teaching Hospital (CHUSO) in Lomé, Togo.

Study design: This was a descriptive cross-sectional study carried out on laboratory data collected from January 1, 2018, to December 31, 2019.

Methodology: The Kirby-Bauer disc diffusion method was used for antibiotic susceptibility testing and the results were interpreted according to the guidelines of the Antibigram Committee of the French Society of Microbiology (CA-SFM, 2018).

Results: A total of 639 samples were collected, including mainly pus (n = 339; 53.1%) and urine (n = 260; 40.7%). The samples were mainly from pediatrics (n=107; 16.7%), intensive care units (n=73; 11.4%) and surgical emergencies (n=72; 11.3%). A total of 698 bacteria were isolated, including mainly *Escherichia coli* (n=247, 35.4%), *Staphylococcus aureus* (n=123, 17.6%), and *Klebsiella pneumoniae* (n=114, 16.3%). *Enterobacteriaceae* strains were resistant to almost all antibiotics tested, except amikacin and ertapenem, which had respective resistance rates of 2.8% and 8.4%. None of the *P. aeruginosa* strains were resistant to piperacillin-tazobactam, whereas 37.9% were resistant to imipenem. Among *A. baumannii* strains, 4.2% and 22.9% were respectively resistant to amikacin and imipenem, whereas 56.3% were resistant to levofloxacin. Almost all *S. aureus* strains (99.2%) were resistant to

penicillin, whereas only 2.4% were resistant to rifampicin. Of the 698 bacteria isolated, the prevalence of multidrug-resistant bacteria (MDR) was 41.3% (n = 288), whereas the prevalence of ESBL-producing *Enterobacteriaceae* was 51.3% (201/392).

Conclusion: We reported various resistance profiles of bacterial species isolated from hospitalized patients at the CHU Sylvanus Olympio, Lomé, Togo. The study of bacterial ecology and resistance in every prefectural, regional, and university teaching hospital would be of great importance to reduce mortality associated with hospital-acquired infections throughout the Togolese territory.

Keywords: antibiotic resistance; hospital-acquired infection; Lomé-Togo; hospitalized patient.

Introduction

Bacterial infections are associated with high morbidity. In 2022, Ikuta et al. [1], reported that bacterial infections were the second leading cause of death worldwide and were responsible for one in eight deaths. Bacterial infections are becoming increasingly difficult to treat because of the increasing rate of antibiotic resistance. Additionally, global surveys have shown that, in 2019, antimicrobial resistance killed more people than HIV/AIDS or malaria[2,3].

Antibiotic-resistant bacteria have contributed to the burden of hospital-acquired infections (HAI), especially in developing countries [4].HAIs have a significant impact on clinical outcomes, length of hospital stay, and extra costs of medical care [5,6].The prevalence of healthcare-associated infections is 25% in low-income countries [7,8]. The most common HAIs are central line-associated bloodstream infections (CLABSI), catheter-associated urinary tract infections (CAUTI), surgical site infections (SSI) and ventilator-associated pneumonia (VAP) [9]. If appropriate measures are not taken, bacteria isolated from

hospitalized patients cause healthcare-associated infections (HAI), particularly in developing countries[10]. Moreover, hospital environments (devices, rooms, surfaces, and air conditioning pipes) are often colonized by bacterial biofilms, which are powerful platforms for intra- and interspecific gene exchanges[11–14]. These intra- and interspecific exchanges of resistance genes in hospitals act as catalysts for antibiotic resistance [15].

Most hospital-acquired bacteria (HAB) are multidrug-resistant (MDR) and extensively drug-resistant bacteria (XDR)[16–18]. The most reported HABs are carbapenem-resistant *Enterobacteriaceae* (CRE), carbapenem-resistant *Pseudomonas aeruginosa* (CRPa), carbapenem-resistant *Acinetobacter baumannii* (CRAb), methicillin-resistant *Staphylococcus aureus* (MRSA), extended-spectrum β -lactamases -producing *Enterobacteriaceae* (ESBL-E), and vancomycin-resistant *Enterococcus* (VRE) [6,19].

Monitoring the susceptibility profiles of bacteria isolated from hospitalized patients is a crucial step leading to the adaptation of empirical antibiotic treatments and better prevention of outbreaks of multidrug-resistant bacteria in hospitals[20,21].

Almost all countries worldwide have established antimicrobial resistance committees to drastically reduce antibiotic resistance-associated mortality [1,22,23] and Togo is part of the same dynamic. Thus, our study aimed to determine the antibiotic resistance profiles of bacteria isolated from hospitalized patients at the Sylvanus Olympio University Teaching Hospital (CHUSO) in Lomé, Togo.

Materials and methods

Study design

This was a descriptive cross-sectional study carried out on laboratory data collected from January 1, 2018, to December 31, 2019, at the Sylvanus Olympio University Teaching Hospital (CHUSO) in Lomé, Togo.

CHUSO (<https://chuso.tg/>) is the largest hospital in Togo, with 43 departments, 838 hospitalization beds, 205 medical staff, 474 paramedical staff, and approximately 27,000 hospitalizations annually.

The inclusion criteria were hospitalization and antibiogram completion. Data from patients hospitalized at the CHUSO who underwent laboratory bacteriological analysis were included in this study. The collected data included department from which the sample came, type of sample, bacteria isolated, and antibiotic susceptibility testing results. Data from non-hospitalized patients were excluded.

Bacterial isolates

The bacteria were isolated and identified using bromocresol purple lactose agar (BPLA), UriSelect chromogenic media (Bio-Rad Laboratories, Marnes-la-Coquette, France), API20E galleries (bioMérieux, Craponne, France) for *Enterobacteriaceae*, Api10S (bioMérieux, Craponne, France) for *S. aureus* and Api20NE (bioMérieux, Craponne, France) for *P. aeruginosa* and *A. baumannii*.

Antibiotic susceptibility testing and ESBL detection

The Kirby-Bauer disc diffusion method was used for antibiotic susceptibility testing and the results were interpreted according to the guidelines of the Antibiogram Committee of the French Society of Microbiology (CA-SFM, 2018). For *Enterobacteriaceae*, following antibiotic were tested: amoxicillin - clavulanic Acid (AMC, 20µg - 10µg), piperacillin (PIP, 30µg), ertapenem (ERT, 10µg), ceftazidime (CTZ, 30µg), ceftriaxone (CTR, 30µg), cefotaxime (CTA, 30µg), amikacin (AMI, 30µg), gentamicin (GEN, 10µg), nalidixic acid (NAL, 30µg), norfloxacin (NOR, 10µg), ciprofloxacin (CIP, 5µg), levofloxacin (LEV, 5µg), and sulfamethoxazole - trimethoprim (SXT, 23.75µg - 1.25µg). For *P. aeruginosa* and *A.*

baumanni strains, following antibiotics were tested: piperacillin – tazobactam (PTZ, 100µg - 10µg), ceftazidime (CTZ, 30µg), imipenem (IMP, 10µg), amikacin (AMI, 30µg), gentamicin (GEN, 10µg), ciprofloxacin (CIP, 5µg), levofloxacin (LEV, 5µg), and sulfamethoxazole – trimethoprim (SXT, 23.75µg - 1.25µg). The following antibiotics were tested for *S. aureus*: penicillin (P, 10µg), ceftazidime (CTZ, 30µg), kanamycin (KAN, 30µg), tobramycin (TOB, 10µg), gentamicin (GEN, 10µg), erythromycin (E, 30µg), tetracycline (TET, 30µg), ciprofloxacin (CIP, 5µg), norfloxacin (NOR, 10µg), rifampicin (RIP, 5µg), and linezolid (LNZ, 30µg).

ESBL production was detected by double-disk synergy test using AMC disc surrounded at a radius of 30 mm by CTR, CTZ and CTA.

Data analysis

Data processing was performed using STATA® statistical processing software version 15. The variables were described by their absolute (n) and relative (%) frequencies. Microsoft Excel® 2019 software was used to make the graphs.

Results

Distribution of samples

A total of 639 samples were collected, including pus (n = 339; 53.1%), urine (n = 260; 40.7%) and blood (n = 40; 6.3%) (Table 1). The samples were mainly from pediatrics (n=107; 16.7%), intensive care units (n=73; 11.4%), surgical emergencies (n=72; 11.3%), and pediatric surgery (n=61; 9.5%). The distribution of the samples according to service is detailed in Table 1.

Table 1. Distribution of samples according to department.

Department	Sample						Total
	Pus		Urine		Blood		
	n	%	n	%	n	%	
Pediatrics	15	14	84	78.5	8	7.5	107
Intensive Care Units	6	8.2	56	76.7	11	15.1	73
Surgical Emergencies	64	88.9	7	9.7	1	1.4	72
Pediatric Surgery	58	95.1	2	3.3	1	1.6	61
Traumatology	48	90.6	4	7.6	1	1.9	53
Gynecology-Obstetrics	32	62.8	18	35.3	1	2	51
Visceral surgery	35	89.7	3	7.7	1	2.6	39
Medical-surgical clinic	22	53.7	15	36.6	4	9.8	41
Oto-Rhino-Laryngology	33	100	0	0	0	0	33
Nephrology	0	0	24	88.9	3	11.1	27
Total	339	53	260	40.7	40	6.3	639

A total of 698 bacteria were isolated from the 639 samples. Several single samples carried two pathogenic bacteria. Among the 698 isolated bacteria, 516 (73.9%) were Gram-negative bacilli, mainly *E. coli* (n=247; 47.9%) and *K. pneumoniae* (n=114; 22.1%) (Table 2).

Table 2. Distribution of bacteria isolated from samples included in the study

Bacteria		n	%
Gram-negative bacilli (n=516)	<i>E. coli</i>	247	47.9
	<i>K. pneumoniae</i>	114	22.1
	<i>A. baumannii</i>	48	9.3

	<i>Enterobacter</i> spp.	31	6.4
	<i>P. aeruginosa</i>	29	5.6
	<i>S. aureus</i>	123	67.6
Gram-positive cocci (n=182)	<i>Streptococcus</i> spp.	23	12.6
	<i>Enterococcus</i> spp.	18	9.9

Antibiotic susceptibility testing

Enterobacteriaceae species included in this antibiotic susceptibility testing, (n=392), were *E. coli* (n=247), *K. pneumoniae* (n=114), and *Enterobacter* spp. (n=31). *Enterobacteriaceae* strains were resistant to almost all antibiotics tested, including piperacillin (93.1%), sulfamethoxazole – trimethoprim (84.9%), amoxicillin – clavulanic acid (71.2%), third-generation cephalosporins (69.9 – 74.7%), fluoroquinolones (61.7 – 70.9%), and gentamicin (50.5%). However, amikacin (2.8%) and ertapenem (8.4%) showed good activity against the *Enterobacteriaceae* strains (Fig 1).

Most antibiotics tested showed good activity against *P. aeruginosa* strains. Thus, the following resistance prevalence has been reported: sulfamethoxazole – trimethoprim (58.6%), imipenem (37.9%), fluoroquinolones (20.7 – 24.1%), ceftazidime (20.7%) and aminoglycosides (17.2%). Furthermore, none of the *P. aeruginosa* strains were resistant to piperacillin-tazobactam. (Fig 2).

The prevalence of resistance in *A. baumannii* strains included: sulfamethoxazole – trimethoprim (66.7%), fluoroquinolones (56.3%), gentamicin (50%), ceftazidime (47.9%) and piperacillin – tazobactam (31.3%). Amikacin (4.2%) and imipenem (22.9%) showed good activity against *A. baumannii* (Fig 3).

Almost all *S. aureus* strains (99.2%) were resistant to penicillin, followed by tetracycline (59.3%), ceftazidime (27.6%), fluoroquinolones (16.3 – 23.6%), erythromycin (17.1%), aminoglycosides (12.2 – 14.6%), linezolid (2.4%) and rifampicin (1.6 %)(Fig 4).




Fig. 1. *Enterobacteriaceae* resistance profiles.




Fig. 2. *P. aeruginosa* resistance profiles




Fig.3. *A. baumannii* resistance profiles.




Fig. 4. *S. aureus* resistance profiles.

Resistance phenotypes

Among the 698 bacteria isolated, the prevalence of MDR was (288/698; 41.3%), whereas the prevalence of ESBL-producing *Enterobacteriaceae* was (201/392; 51.3%). The prevalence of methicillin resistant *Staphylococcus aureus* (MRSA) was 27.6%.

Discussions

This study reported bacteria from patients hospitalized in ten departments. Most samples were obtained from the pediatric department (16.7%). This predominance can be explained by the age and immaturity of the babies' immune systems, which favor infections.

Almost half of the samples were pus (53.05%), followed by urine (40.69%). The same trend was reported in Guinea Conakry, where Keita et al. found a predominance of pus (67.7%) and urine (16.1%) [24]. These two types of samples were mainly reported in a study by Kakupa et al. in Democratic republic of Congo [25]. Fasla and Khaleq, in Morocco reported Cerebrospinal Fluid (CSF) (34.69%), followed by pus (29.59%) [26]. The fact that Fasla and Khaleq. reported only patients from emergency department, may explain this discrepancy.

A total of 471 Gram-negative bacteria and 164 Gram-positive bacteria have been reported. This trend was also reported in Cameroon and Morocco [27,28]. Among the Gram-negative bacteria isolated, *Enterobacteriaceae* occupied the first place. A similar trend was reported in Morocco by Mortaji [29] and Soraa [28]. This predominance of *Enterobacteriaceae* can be explained by the fact that they are mostly commensal in the human digestive tract and widely found in the environment. Moreover, *Enterobacteriaceae* are often the predominant bacteria found in clinical settings [30–32].

Among the *Enterobacteriaceae*, *E. coli*, were resistant to ciprofloxacin (70.9%), gentamicin (48.2), carbapenems (8.4%) and amikacin (2.8%). Mlaga et al. [33] also reported *E. coli* strains with decreased susceptibility to fluoroquinolones and gentamicin, and high susceptibility to amikacin and carbapenems. Sbiti et al. in 2017 [34], also reported notable resistance to ciprofloxacin (92.5%) and good susceptibility to carbapenem (3.4%) and amikacin (6.1 %). In Senegal, Dossouvi et al. in 2022 and 2023 [35,36] also reported high *Enterobacteriaceae* resistance rates to ciprofloxacin and low resistance rates to carbapenems

and Amikacin. The high rate of resistance to fluoroquinolones in *Enterobacteriaceae* compromises the use of this class of antibiotics in probabilistic antibiotic therapy. This can be explained by the extensive use of fluoroquinolones as an empirical treatment for urinary infections.

Fluoroquinolones and aminoglycosides showed good activities against *S. aureus* and rifampicin whereas linezolid showed excellent activity. Tălăpan et al. [37] reported in Romania, resistance profiles very similar to ours concerning rifampicin, linezolid, fluoroquinolones, penicillin and tetracycline. Rao et al. [38] reported similar resistance patterns for gentamicin, rifampicin, and linezolid.

P. aeruginosa strains were more than 30% resistant to carbapenems, 24% to ciprofloxacin and 17% to amikacin. Abdallah et al in Tunisia reported almost similar results, 19.6% resistant to carbapenem, 21.6% to ciprofloxacin and 19.2% to amikacin [39]. Contrary to our results, high prevalences of ceftazidime resistance (66–70%) have been reported in Libya, Tunisia, Egypt [40] and higher prevalences of piperacillin-tazobactam resistance were observed in 2023, in Palestine [41], in Chad [42] and in Saudi Arabia [43]. A concern was the prevalence of carbapenem-resistant *P. aeruginosa* (37.9%). These carbapenem-resistant *P. aeruginosa* (CRPa) could be the starting point for hospital colonization and the intra- and inter-specific transfer of carbapenem-resistant genetic determinants. If appropriate solutions are not taken, CRB epidemics could affect CHUSO as reported worldwide [44–47].

Concerning *A. baumannii* strains, our results are similar to those obtained by Musyoki et al. [48] in Kenya for amikacin. Amikacin appears to be a good therapeutic option for *A. baumannii* infection in Africa. However, in Turkey and Iran, high prevalence rates of amikacin resistance ranging from 66.7% to 100% have been reported [49,50]. Piperacillin-tazobactam is known to be a key antibiotic against *A. baumannii* [51]. Contrary to our results (resistance rate of 31.3%), several studies have reported a high prevalence of resistance to piperacillin-

tazobactam, ranging from 62 to 100% in Benin, Tanzania, Ghana, Morocco, and South Africa[52,53].

More than half of the *Enterobacteriaceae* strains were ESBL producers. According to the prevalence of ESBL-producing *Enterobacteriaceae* reported by Mlaga et al. [33] (25.95%; strains collected from 2009 to 2010), and Toudji et al. [54] (22.4%, strains collected from 2009 to 2011), the prevalence of ESBL-producing *Enterobacteriaceae* is constantly increasing at CHUSO. The evolution of ESBL-producing *Enterobacteriaceae* prevalence at CHUSO will need to be carefully monitored every year.

Conclusion

We reported various resistance profiles of bacterial species isolated from hospitalized patients at the CHU Sylvanus Olympio, Lomé, Togo. Around a quarter of the *P. aeruginosa* and *A. baumannii* strains were resistant to carbapenems. In addition, ciprofloxacin should no longer be prescribed as a probabilistic antibiotic in hospitalized patients in the CHUSO. Moreover, amikacin may be a good alternative for carbapenem-resistant bacteria. However, its prescription must be closely monitored to delay the appearance and generalization of clones resistant to amikacin in Togo. Furthermore, Tobramycin, rifampicin, and linezolid may be good probabilistic antibiotics for *S. aureus*-associated infections. Our study had some limitations, such as the fact that we did not determine the distribution of antibiotic resistance rates according to age, sex, and diagnosis. Finally, the study of bacterial ecology and bacterial resistance in every prefectural, regional, and university teaching hospital would be of great importance to reduce mortality associated with hospital-acquired infections throughout the Togolese territory.

Ethical approval and Consent

The Institutional Review Board (IRB) of the Sylvanus Olympio Teaching Hospital approved the study protocol, and the collected data were only used for clinical research purposes. The information was kept confidential and was not used for any other purpose. Patient information was coded to protect their identities. Since retrospective data were used, the IRB of the Sylvanus Olympio Teaching Hospital obtained all participants' consent for any further research. The authors confirmed that all the methods were performed in accordance with the relevant guidelines and regulations.

References

- [1] Ikuta KS, Swetschinski LR, Aguilar GR, Sharara F, Mestrovic T, Gray AP, et al. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* 2022;400:2221–48.
[https://doi.org/10.1016/S0140-6736\(22\)02185-7](https://doi.org/10.1016/S0140-6736(22)02185-7).
- [2] Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet* 2022;399:629–55. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0).
- [3] Thompson T. The staggering death toll of drug-resistant bacteria. *Nature* 2022.
<https://doi.org/10.1038/d41586-022-00228-x>.
- [4] Abban MK, Ayerakwa EA, Mosi L, Isawumi A. The burden of hospital acquired infections and antimicrobial resistance. *Heliyon* 2023;9:e20561.
<https://doi.org/10.1016/j.heliyon.2023.e20561>.
- [5] Gidey K, Gidey MT, Hailu BY, Gebreamlak ZB, Niriayo YL. Clinical and economic burden of healthcare-associated infections: A prospective cohort study. *PLOS ONE* 2023;18:e0282141. <https://doi.org/10.1371/journal.pone.0282141>.

- [6] Wang M, Wei H, Zhao Y, Shang L, Di L, Lyu C, et al. Analysis of multidrug-resistant bacteria in 3223 patients with hospital-acquired infections (HAI) from a tertiary general hospital in China. *Bosn J Basic Med Sci* 2019;19:86–93.
<https://doi.org/10.17305/bjbms.2018.3826>.
- [7] Abubakar U, Amir O, Rodríguez-Baño J. Healthcare-associated infections in Africa: a systematic review and meta-analysis of point prevalence studies. *Journal of Pharmaceutical Policy and Practice* 2022;15:99. <https://doi.org/10.1186/s40545-022-00500-5>.
- [8] Raoofi S, Pashazadeh Kan F, Rafiei S, Hosseinipalangi Z, Noorani Mejareh Z, Khani S, et al. Global prevalence of nosocomial infection: A systematic review and meta-analysis. *PLoS One* 2023;18:e0274248. <https://doi.org/10.1371/journal.pone.0274248>.
- [9] Monegro AF, Muppidi V, Regunath H. Hospital-Acquired Infections. StatPearls, Treasure Island (FL): StatPearls Publishing; 2023.
- [10] Rosenthal VD. Health-care-associated infections in developing countries. *The Lancet* 2011;377:186–8. [https://doi.org/10.1016/S0140-6736\(10\)62005-3](https://doi.org/10.1016/S0140-6736(10)62005-3).
- [11] Liu W, Røder HL, Madsen JS, Bjarnsholt T, Sørensen SJ, Burmølle M. Interspecific Bacterial Interactions are Reflected in Multispecies Biofilm Spatial Organization. *Frontiers in Microbiology* 2016;7.
- [12] Luo A, Wang F, Sun D, Liu X, Xin B. Formation, Development, and Cross-Species Interactions in Biofilms. *Front Microbiol* 2022;12:757327.
<https://doi.org/10.3389/fmicb.2021.757327>.
- [13] Comolli L. Intra- and inter-species interactions in microbial communities. *Frontiers in Microbiology* 2014;5:629. <https://doi.org/10.3389/fmicb.2014.00629>.

- [14] Dossim S. Ecologie bactérienne de l'environnement et du matériel lors des différentes étapes de stérilisation au bloc opératoire du CHU Sylvanus Olympio à Lomé au Togo 2017.
- [15] Lerminiaux NA, Cameron ADS. Horizontal transfer of antibiotic resistance genes in clinical environments. *Can J Microbiol* 2019;65:34–44. <https://doi.org/10.1139/cjm-2018-0275>.
- [16] Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. *Expert Opin Pharmacother* 2014;15:1351–70. <https://doi.org/10.1517/14656566.2014.914172>.
- [17] Sadeghi H, Khoei SG, Bakht M, Rostamani M, Rahimi S, Ghaemi M, et al. A retrospective cross-sectional survey on nosocomial bacterial infections and their antimicrobial susceptibility patterns in hospitalized patients in northwest of Iran. *BMC Res Notes* 2021;14:88. <https://doi.org/10.1186/s13104-021-05503-0>.
- [18] Shi J, Sun T, Cui Y, Wang C, Wang F, Zhou Y, et al. Multidrug resistant and extensively drug resistant *Acinetobacter baumannii* hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit. *BMC Infectious Diseases* 2020;20:597. <https://doi.org/10.1186/s12879-020-05321-y>.
- [19] Sikora A, Zahra F. Nosocomial Infections. StatPearls, Treasure Island (FL): StatPearls Publishing; 2023.
- [20] Perez F, Villegas MV. The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria. *Curr Opin Infect Dis* 2015;28:375–83. <https://doi.org/10.1097/QCO.0000000000000182>.
- [21] Wall S. Prevention of antibiotic resistance – an epidemiological scoping review to identify research categories and knowledge gaps. *Global Health Action* 2019;12:1756191. <https://doi.org/10.1080/16549716.2020.1756191>.

- [22] Bank W, Organization WH. Sustaining Action Against Antimicrobial Resistance: A Case Series of Country Experiences 2022.
- [23] World Health Organization. 13 critical interventions that support countries to address antimicrobial resistance in human health 2023. <https://www.who.int/news/item/19-10-2023-13-critical-interventions-that-support-countries-to-address-antimicrobial-resistance-in-human-health> (accessed January 8, 2024).
- [24] Keita AK, Doumbouya N, Sow MS, Konaté B, Dabo Y, Panzo DA, et al. Prévalence des infections nosocomiales dans deux hôpitaux de Conakry (Guinée). *Santé Publique* 2016;28:251–5. <https://doi.org/10.3917/spub.162.0251>.
- [25] Kakupa DK, Muenze PK, Byl B, Wilmet MD. Etude de la prévalence des infections nosocomiales et des facteurs associés dans les deux hopitaux universitaires de Lubumbashi, République Démocratique du Congo: cas des Cliniques Universitaires de Lubumbashi et l'Hôpital Janson Sendwe. *Pan Afr Med J* 2016;24:275. <https://doi.org/10.11604/pamj.2016.24.275.7626>.
- [26] Fasla A, Khaleq K. Apport des prélèvements bactériologiques aux urgences Thèse pharm 2011, Univ Caddi Ayyad, Marrakech.
- [27] Gonsu HK, Epée E, Matalom C, Ngobo A, Toukam M, Moukouri E. Profil bactériologique et sensibilité aux antibiotiques des germes isolés des infections de la surface à Yaoundé. *Health sciences and disease* 2013;14.
- [28] Sora N, Zougaghi L, Zahlane K, Admou B, Haouach K, Kachach M, et al. Épidémiologie et profil de sensibilité des isolats d'hémocultures dans un centre hospitalo-universitaire Marocain. *Epidemiology and susceptibility profile of blood culture isolates in a Moroccan university hospital center*.
- [29] Mortaji A. Ecologie bactérienne en réanimation et profil de résistance aux antibiotiques. Université CADI-AYYAD. Marrakech, 2019.

- [30] Resendiz-Nava CN, Silva-Rojas HV, Rebollar-Alviter A, Rivera-Pastrana DM, Mercado-Silva EM, Nava GM. A Comprehensive Evaluation of *Enterobacteriaceae* Primer Sets for Analysis of Host-Associated Microbiota. *Pathogens* 2022;11:17. <https://doi.org/10.3390/pathogens11010017>.
- [31] Mirzaei B, Babaei R, Bazgir ZN, Goli HR, Keshavarzi S, Amiri E. Prevalence of *Enterobacteriaceae* spp. and its multidrug-resistant rates in clinical isolates: A two-center cross-sectional study. *Mol Biol Rep* 2021;48:665–75. <https://doi.org/10.1007/s11033-020-06114-x>.
- [32] Tilahun M, Kassa Y, Gedefie A, Ashagire M. Emerging Carbapenem-Resistant *Enterobacteriaceae* Infection, Its Epidemiology and Novel Treatment Options: A Review. *IDR* 2021;14:4363–74. <https://doi.org/10.2147/IDR.S337611>.
- [33] Mlaga D, Salou M, Dossim S, Tigossou S, Anago A, Dagnra A, et al. Antibiotic Resistance Profile and Molecular Characterization of *Escherichia coli* Extended-Spectrum Beta-Lactamase-Producing Isolated from Sylvanus Olympio Teaching Hospital in Lomé, Togo. *Journal of Advances in Microbiology* 2019;14:1–7. <https://doi.org/10.9734/JAMB/2019/46439>.
- [34] Sbiti M, Lahmadi khalid, louzi L. Profil épidémiologique des entérobactéries uropathogènes productrices de bêta-lactamases à spectre élargi. *Pan Afr Med J* 2017;28:29. <https://doi.org/10.11604/pamj.2017.28.29.11402>.
- [35] Dossouvi K, Samb-Ba B, Lo G, Cissé A, Diallo A, Ndiaye I, et al. Molecular Characterization of Extended-Spectrum Beta-Lactamase-Producing Extra-Intestinal Pathogenic *Escherichia coli* Isolated in an University Teaching Hospital Dakar-Senegal. *Austin Journals* 2022.
- [36] Dossouvi KM, Ba BS, Lo G, Cissé A, Ba-Diallo A, Ndiaye I, et al. Molecular Characterization of Clinical Strains of Extended-Spectrum Beta-Lactamases-Producing

- Klebsiella Pneumoniae* Isolated in A Tertiary Hospital in Dakar-Senegal. Archives of Microbiology & Immunology 2023;7:1–9.
- [37] Tălăpan D, Sandu A-M, Rafila A. Antimicrobial Resistance of *Staphylococcus aureus* Isolated between 2017 and 2022 from Infections at a Tertiary Care Hospital in Romania. Antibiotics 2023;12:974. <https://doi.org/10.3390/antibiotics12060974>.
- [38] Rao S, Linke L, Magnuson R, Jauch L, Hyatt DR. Antimicrobial resistance and genetic diversity of *Staphylococcus aureus* collected from livestock, poultry and humans. One Health 2022;15:100407. <https://doi.org/10.1016/j.onehlt.2022.100407>.
- [39] Abdallah HB, Noomen S, Khélifa ABE, Sahnoun O, Elargoubi A, Mastouri M. Profil de sensibilité aux antibiotiques des souches de *Pseudomonas aeruginosa* isolées dans la région de Monastir. Médecine et Maladies Infectieuses 2008;38:554–6. <https://doi.org/10.1016/j.medmal.2008.05.002>.
- [40] Al-Orphaly M, Hadi HA, Eltayeb FK, Al-Hail H, Samuel BG, Sultan AA, et al. Epidemiology of Multidrug-Resistant *Pseudomonas aeruginosa* in the Middle East and North Africa Region. MSphere 2021;6:e00202-21. <https://doi.org/10.1128/mSphere.00202-21>.
- [41] Shbaita S, Abatli S, Sweileh MW, Aiesh BM, Sabateen A, Salameh HT, et al. Antibiotic resistance profiles and associated factors of *Pseudomonas* Infections among patients admitted to large tertiary care hospital from a developing country. Antimicrobial Resistance & Infection Control 2023;12:149. <https://doi.org/10.1186/s13756-023-01355-4>.
- [42] Ahmat AM, Bolti MA, Yandai FH, Alio HM, Baane M-P, Djibrine MA, et al. Antimicrobial Resistance of *Pseudomonas aeruginosa* Isolated from Human Infections in N'Djamena, Chad. Open Journal of Medical Microbiology 2023;13:17–30. <https://doi.org/10.4236/ojmm.2023.131002>.

- [43] Momenah AM, Bakri RA, Jalal NA, Ashgar SS, Felemban RF, Bantun F, et al. Antimicrobial Resistance Pattern of *Pseudomonas aeruginosa*: An 11-Year Experience in a Tertiary Care Hospital in Makkah, Saudi Arabia. *Infect Drug Resist* 2023;16:4113–22. <https://doi.org/10.2147/IDR.S409726>.
- [44] Ledda A, Cummins M, Shaw LP, Jauneikaite E, Cole K, Lasalle F, et al. Hospital outbreak of carbapenem-resistant Enterobacterales associated with a bla OXA-48 plasmid carried mostly by *Escherichia coli* ST399. *Microb Genom* 2022;8:000675. <https://doi.org/10.1099/mgen.0.000675>.
- [45] Zeng L, Yang C, Zhang J, Hu K, Zou J, Li J, et al. An Outbreak of Carbapenem-Resistant *Klebsiella pneumoniae* in an Intensive Care Unit of a Major Teaching Hospital in Chongqing, China. *Front Cell Infect Microbiol* 2021;11:656070. <https://doi.org/10.3389/fcimb.2021.656070>.
- [46] Catho G, Martischang R, Boroli F, Chraïti MN, Martin Y, Koyluk Tomsuk Z, et al. Outbreak of *Pseudomonas aeruginosa* producing VIM carbapenemase in an intensive care unit and its termination by implementation of waterless patient care. *Critical Care* 2021;25:301. <https://doi.org/10.1186/s13054-021-03726-y>.
- [47] Quiles MG, Carlesse F, Silva MAA da, Mingrone RC, Fonseca JM, Silva DC, et al. High mortality outbreak of carbapenem-resistant *Pseudomonas aeruginosa* infection in a Brazilian pediatric oncology hospital. *Braz J Infect Dis* 2017;21:205–6. <https://doi.org/10.1016/j.bjid.2016.10.012>.
- [48] Musyoki VM, Masika MM, Mutai W, Wilfred G, Kuria A, Muthini F. Antimicrobial susceptibility pattern of *Acinetobacter* isolates from patients in Kenyatta National Hospital, Nairobi, Kenya. *Pan Afr Med J* 2019;33:146. <https://doi.org/10.11604/pamj.2019.33.146.17220>.

- [49] Moosavian M, Khoshkholgh Sima M, Ahmad Khosravi N, Abbasi Montazeri E. Detection of OqxAB Efflux Pumps, a Multidrug-Resistant Agent in Bacterial Infection in Patients Referring to Teaching Hospitals in Ahvaz, Southwest of Iran. *International Journal of Microbiology* 2021;2021:e2145176. <https://doi.org/10.1155/2021/2145176>.
- [50] Konca C, Tekin M, Geyik M. Susceptibility Patterns of Multidrug-Resistant *Acinetobacter baumannii*. *Indian J Pediatr* 2021;88:120–6. <https://doi.org/10.1007/s12098-020-03346-4>.
- [51] Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant *Acinetobacter baumannii* strains. *Antimicrob Agents Chemother* 2004;48:1586–92. <https://doi.org/10.1128/AAC.48.5.1586-1592.2004>.
- [52] Agyepong N, Fordjour F, Owusu-Ofori A. Multidrug-resistant *Acinetobacter baumannii* in healthcare settings in Africa. *Frontiers in Tropical Diseases* 2023;4.
- [53] Nogbou N-D, Phofa DT, Nchabeleng M, Musyoki AM. Investigating multi-drug resistant *Acinetobacter baumannii* isolates at a tertiary hospital in Pretoria, South Africa. *Indian Journal of Medical Microbiology* 2021;39:218–23. <https://doi.org/10.1016/j.ijmmb.2021.03.005>.
- [54] Toudji AG. Prevalence of Extend Spectrum Beta Lactamases Producing *Enterobacteriaceae* and their Antibiotic Susceptibility in Lome, Togo. *Asian Journal of Life Sciences* 2017.